Baylor, GE Medical Launch ‘The Health Channel’

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 4
Volume 8
Issue 4

HOUSTON-GE Medical Systems and Baylor College of Medicine have launched a 24-hour satellite programming service to deliver accredited, continuing education for physicians, nurses, and other allied health professionals directly to hospitals.

HOUSTON—GE Medical Systems and Baylor College of Medicine have launched a 24-hour satellite programming service to deliver accredited, continuing education for physicians, nurses, and other allied health professionals directly to hospitals.

The new service, called The Health Channel, is directed by Baylor College of Medicine and Texas Children’s Hospital, and is available through GE Medical Systems’ TiP-TV satellite broadcast network. Currently, 1,600 health care facilities in the US, Canada, and Europe provide TiP-TV programming to their staff.

Programs are developed and accredited by Baylor in cooperation with a consortium of leading academic medical institutions, including The Cleveland Clinic Foundation, Duke University Medical Center, the Mayo Clinic, M.D. Anderson Cancer Center, and others.

Programs repeat frequently to accommodate various day and night staff schedules. The channel runs 24 hours a day, 7 days a week, with new programming offered every week. A bi-monthly broadcast guide lists dates and times.

The monthly subscription rate for The Health Channel varies depending on hospital bed size and can range from $750 to $3,000. Hospitals can subscribe by calling toll free 1-877-GE TiPTV (1-877-438-4788). More information on the new service is available at the Channel’s website, www.healthchannelweb.com.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
2 experts in this video
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
2 experts in this video
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
Related Content